Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease

摘要

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,;;which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

主权项

1. A compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, wherein R31 is selected from —H, and -(optionally substituted C1-6 alkyl); R36 is selected from —H, -(optionally substituted C1-6 alkyl), -(optionally substituted C3-7 carbocyclyl), —C1-4 alkyl-(optionally substituted C3-7 carbocyclyl), -(optionally substituted heterocyclyl having 3 to 7 ring atoms), and —C1-4 alkyl-(optionally substituted heterocyclyl having 3 to 7 ring atoms); R38 is selected from —H, -(optionally substituted C1-6 alkyl), -(optionally substituted C3-7 carbocyclyl), —C1-4 alkyl-(optionally substituted C3-7 carbocyclyl), -(optionally substituted heterocyclyl having 3 to 7 ring atoms), and C1-4 alkyl-(optionally substituted heterocyclyl having 3 to 7 ring atoms); R39 is selected from a -(optionally substituted C1-6 alkyl), -(optionally substituted C3-9 carbocyclyl), —C1-4 alkyl-(optionally substituted C3-9 carbocyclyl), -(optionally substituted heterocyclyl having 3 to 9 ring atoms), and —C1-4 alkyl-(optionally substituted heterocyclyl having 3 to 9 ring atoms), wherein the alkyl group can be saturated or unsaturated; X32 is selected from NR36, N(R36)C(O), C(O)NR36, O, C(O), C(O)O, OC(O); N(R36)SO2, SO2N(R36), S, SO, and SO2; Hal is a halogen; s is 0 to 4; wherein the alkyl group can be optionally substituted with one or more substituents which are independently selected from —(CH2)s—X32—R38, —C3-7 carbocyclyl, -(heterocyclyl having 3 to 7 ring atoms), -halogen, —CN, and —CF3; and wherein the heterocyclyl group and/or carbocyclyl group can be optionally substituted with one or more substituents which are independently selected from —(CH2)s—X32—R38, -halogen, —CN, —CF3, —C1-6 alkyl, —C3-7 carbocyclyl which is optionally substituted by —OH or -Hal, —C1-4 alkyl—C3-7 carbocyclyl which is optionally substituted by —OH or -Hal, -(heterocyclyl having 3 to 7 ring atoms which is optionally substituted by —OH or -Hal), and —C1-4 alkyl-(heterocyclyl having 3 to 7 ring atoms which is optionally substituted by —OH or -Hal).